RxDoctor Payments Data

Muhammad Mustafa, MD

Cardiovascular Disease · Winter Haven, FLNPI 1932480688

Payments from drug & device makers

$23,939in general payments, 2019–2025

Across 475 payments — averaging $50.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$13K
  • Coala Life Inc$3K
  • Boston Scientific$1K
  • Amgen$1K
  • Boehringer Ingelheim$853
  • AstraZeneca$742
  • plus $4K from 27 others

What the payments were for

  • Consulting fees$2,70011%
  • Speaking & faculty fees$11,92850%
  • Travel & lodging$2891%
  • Food & beverage$8,86637%
  • Education$1561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,939 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$850,697
Medicare patients
2,278
Services billed
11,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban776$765,641
EntrestoSacubitril/Valsartan554$600,289
JardianceEmpagliflozin184$183,677
FarxigaDapagliflozin Propanediol149$152,358
Repatha SureclickEvolocumab222$151,089
XareltoRivaroxaban126$149,542
Dabigatran EtexilateDabigatran Etexilate Mesylate41$11,306
Metoprolol Succinate641$9,533
Praluent PenAlirocumab15$9,489
VascepaIcosapent Ethyl17$7,318
Carvedilol335$3,333
Diltiazem 24hr Er (Cd)Diltiazem Hcl113$3,292
Atorvastatin Calcium299$3,272
Rosuvastatin Calcium255$3,084
Amlodipine Besylate441$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$483$765,641776 claims
NovartisEntresto$13,015$600,289554 claims
Boehringer IngelheimJardiance$853$183,677184 claims
AstraZenecaFarxiga$742$152,358149 claims
Johnson & JohnsonXarelto$270$149,542126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →